None listed
Conditions
Brief summary
Introduction & aims Tranexamic acid (TXA) is an anti-fibrinolytic historically been used to reduce haemorrhage during trauma. Its benefits in reducing the blood loss and subsequent blood transfusions after elective total joint replacements (TJR) have been widely accepted. Despite this, tranexamic acid has yet to be routinely used in all patients – mostly due to the theoretical concern of an increased incidence of venous thromboembolism. This study aims to determine whether the use of TXA in TJR increases the risk of venous thromboembolism. Method A retrospective audit of consecutive patients undergoing a TJR between July 2016 and June 2018 was performed at TQEH. Patient demographics, history of thromboembolic events and American Society of Anaesthesiologists (ASA) scores were identified. This was then analysed against the incidence of a post-operative thromboembolic event. Patients who did not receive TXA were further investigated as to the reason for withholding
Interventions
A retrospective audit of consecutive patients undergoing a TJR between July 2016 and
June 2018 was performed at TQEH. Patient demographics, history of thromboembolic
events and American Society of Anaesthesiologists (ASA) scores were identified. This was
then analysed against the incidence of a post-operative thromboembolic event. Patients
who did not receive TXA were further investigated as to the reason for withholding.
Sponsors
David Campbell
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
consecutive patients undergoing a TJR between July 2016 and June 2018 was performed at TQEH.
Exclusion criteria
nil
Outcome results
None listed